IM-12, an effective GSK-3β inhibitor(IC50=53 nM), regulates Wnt signalling.

GSK-3β:53 nM

In human neural progenitor cells (hNPCs) with an IC50 of 3.8 μM, IM-12 inhibits GSK-3β activity and increases the concentration of β-catenin. IM-12 promotes cell proliferation in human neural progenitor cells by activating the Wnt signaling pathway.

GSK-3β activity assay: IC50 of new synthesised compound IM-12 to GSK-3β is determined by a luminometric GSK-3β activity assay. Briefly, compounds are tested in different concentrations diluted in assay buffer containing final concentrations of: 4 mM MOPS pH 7.2; 0.4 mM EDTA; 1 mM EGTA; 2.5 mM β-glycerophosphate; 4 mM MgCl2; 40 μM BSA; 0.05 mM DTT. Four microlitres of diluted compounds are added to 25 μM pGS-2 peptide substrate, 20 ng recombinant GSK-3β and 1 μM ATP to a total assay volume of 40 μl. The enzymatic reaction is stopped after 30 min of incubation at 30 °C by adding 40 μl KinaseGlo. The luminometric signal is allowed to stabilise for 10 min and the measured with a Glomax? 96 Microplate Luminometer.

To measure viable cells, 50-100 μL of cell suspension is analyzed using CASY technology with the appropriate program. ReNcell VM cells are seeded at a defined cell number and proliferated for 24 h. Then the medium is changed to proliferation medium with added substances at indicated concentrations. The cell number was determined every 24 h. Cells were exposed to the added drugs during the whole experiment, whereas the media is changed every 24 h.(Only for Reference)

DMSO: 65 mg/mL (172.23 mM), Sonication is recommended.

Ethanol: 10 mg/mL (26.5 mM), Heating is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.3 mM), Sonication is recommended.